Download biomedica product list
C4d a biomarker of transplant rejection
In kidney transplantation recipients antibody mediated rejection (AMR) is a common complication that contributes to graft loss. C4d staining in kidney biopsies is widely used to identify the presence of complement activation in the small blood vessels of the kidney. Therefore C4d has been recognized as a marker for identifying AMR in kidney transplants (1).
C4d a biomarker of transplant rejection
C4d antibodies by Biomedica – for the identification of human complement split product C4d in paraffin and frozen sections as well as by flow cytometry.
Anti-C4d Antibody | BI-RC4D
- widely cited in over 90 citations
- for immunohistochemistry on paraffin embedded tissue and frozen sections
- use in kidney, heart, liver and other transplants
Anti-C4d Antibody (FITC) | BI-RC4D-FITC
- protocol for cell- or solid-phase bound C4 and C4d split product by flow cytometry
- for kidney, heart, liver and other transplants
The Biomedica C4d antibody was highlighted in the following publication: Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection. “Complement split product C4d staining was performed by immunochemical analysis of paraffin sections using polyclonal human anti‐C4d antibodies (Biomedica Gruppe, Vienna, Austria)”.
Literature
1. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, Akalin E, Alachkar N, Bagnasco S, Becker JU, Cornell LD, Clahsen-van Groningen MC, Demetris AJ, Dragun D, Duong van Huyen JP, Farris AB, Fogo AB, Gibson IW, Glotz D, Gueguen J, Kikic Z, Kozakowski N, Kraus E, Lefaucheur C, Liapis H, Mannon RB, Montgomery RA, Nankivell BJ, Nickeleit V, Nickerson P, Rabant M, Racusen L, Randhawa P, Robin B, Rosales IA, Sapir-Pichhadze R, Schinstock CA, Seron D, Singh HK, Smith RN, Stegall MD, Zeevi A, Solez K, Colvin RB, Mengel M. Am J Transplant. 2020 Sep;20(9):2318-2331. doi: 10.1111/ajt.15898. Epub 2020 May 28. PMID: 32463180; PMCID: PMC7496245.